Advertisement

Intensive Care Medicine

, Volume 37, Issue 1, pp 86–96 | Cite as

Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis

  • The SAFE Study InvestigatorsEmail author
Original

Abstract

Purpose

To determine the effect of random assignment to fluid resuscitation with albumin or saline on organ function and mortality in patients with severe sepsis.

Methods

Pre-defined subgroup analysis of a randomized controlled trial conducted in the intensive care units of 16 hospitals in Australia and New Zealand.

Results

Of 1,218 patients with severe sepsis at baseline, 603 and 615 were assigned to receive albumin and saline, respectively. The two groups had similar baseline characteristics. During the first 7 days mean arterial pressure was similar in the two groups, but patients assigned albumin had a lower heart rate on days 1 and 3 (p = 0.002 and p = 0.03, respectively) and a higher central venous pressure on days 1–3 (p < 0.005 each day). There was no difference in the renal or total Sequential Organ Failure Assessment score of the two groups; 113/603 (18.7%) of patients assigned albumin were treated with renal replacement therapy compared to 112/615 (18.2%) assigned saline (p = 0.98).

The unadjusted relative risk of death for albumin versus saline was 0.87 [95% confidence interval (CI) 0.74–1.02] for patients with severe sepsis and 1.05 (0.94–1.17) for patients without severe sepsis (p = 0.06 for heterogeneity). From multivariate logistic regression analysis adjusting for baseline factors in patients with complete baseline data (919/1,218, 75.5%), the adjusted odds ratio for death for albumin versus saline was 0.71 (95% CI: 0.52–0.97; p = 0.03).

Conclusions

Administration of albumin compared to saline did not impair renal or other organ function and may have decreased the risk of death.

Keywords

Critical care Fluid therapy Sepsis Mortality Multicenter randomized clinical trial 

Notes

Acknowledgments

Funding bodies are listed alphabetically (Australia unless otherwise stated): Auckland District Health Board, New Zealand; Australian Commonwealth Department of Health and Aged Care; CSL Limited, Melbourne, Victoria; Middlemore Hospital, New Zealand; Australian National Health and Medical Research Council; Health Department of Western Australia; Health Research Council of New Zealand; New South Wales Health Department; Northern Territory Health Services; Queensland Health Services Department; Royal Hobart Hospital, Tasmania; South Australian Department of Human Services; Victorian Department of Human Services. The funding bodies played no part in the conduct or analysis of the study, or the decision to publish the results.

Supplementary material

134_2010_2039_MOESM1_ESM.doc (146 kb)
Supplementary material 1 (DOC 147 kb)

References

  1. 1.
    Dellinger R, Levy M, Carlet J, Bion J, Parker M, Jaeschke R, Reinhart K, Angus D, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini J, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson B, Townsend S, Vender J, Zimmerman J, Vincent JL (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Intensive Care Med 34:17–60CrossRefPubMedGoogle Scholar
  2. 2.
    Schortgen F, Deye N, Brochard L (2004) Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 30:2222–2229CrossRefPubMedGoogle Scholar
  3. 3.
    Miletin MS, Stewart TE, Norton PG (2002) Influences on physicians’ choices of intravenous colloids. Intensive Care Med 28:917–924CrossRefPubMedGoogle Scholar
  4. 4.
    Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911–916CrossRefPubMedGoogle Scholar
  5. 5.
    Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, the German Competence Network Sepsis (SepNet) (2008) Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis. N Engl J Med 358:125–139CrossRefPubMedGoogle Scholar
  6. 6.
    Schortgen F, Girou E, Deye N, Brochard L (2008) The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 34:2157–2168CrossRefPubMedGoogle Scholar
  7. 7.
    Maitland K, Pamba A, English M, Peshu N, Marsh K, Newton C, Levin M (2005) Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 40:538–545CrossRefPubMedGoogle Scholar
  8. 8.
    Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CR, Levin M, Maitland K (2006) Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 1:e21CrossRefPubMedGoogle Scholar
  9. 9.
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341:403–409CrossRefPubMedGoogle Scholar
  10. 10.
    The SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256CrossRefGoogle Scholar
  11. 11.
    ANZICS Clinical Trials Group and Institute for International Health SAFE Study Investigators. The Saline vs. Albumin Fluid Evaluation (SAFE) Study (ISRCTN76588266): design and conduct of a multi-centre, blinded randomised controlled trial of intravenous fluid resuscitation in critically ill patients. http://bmj.com/cgi/content/full/326/7389/559/DC1 Accessed May 18 2010
  12. 12.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655Google Scholar
  13. 13.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher Jr CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709CrossRefPubMedGoogle Scholar
  14. 14.
    Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800PubMedGoogle Scholar
  15. 15.
    TheSAFE Study Investigators (2006) Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 333:1044–1046CrossRefGoogle Scholar
  16. 16.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829CrossRefPubMedGoogle Scholar
  17. 17.
    Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J, the ANZICS CTG Sepsis Investigators (2004) Adult population incidence of severe sepsis in Australian and New Zealand Intensive Care Units. Intensive Care Med 30:589–596CrossRefPubMedGoogle Scholar
  18. 18.
    Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, la-Kokko TI, Kolho E, Rintala EM (2007) Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 33:435–443CrossRefPubMedGoogle Scholar
  19. 19.
    Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le G Jr, Payen D (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353CrossRefPubMedGoogle Scholar
  20. 20.
    NICE-SUGAR Study Investigators (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1346–1349CrossRefGoogle Scholar
  21. 21.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, the Early goal Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377CrossRefPubMedGoogle Scholar
  22. 22.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871CrossRefPubMedGoogle Scholar
  23. 23.
    Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367CrossRefPubMedGoogle Scholar
  24. 24.
    Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Gardlund B, Marshall JC, Rhodes A (2008) Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 34:1935–1947CrossRefPubMedGoogle Scholar
  25. 25.
    Finfer S (2008) Corticosteroids in Septic Shock. N Engl J Med 358:188–190CrossRefPubMedGoogle Scholar
  26. 26.
    The Australasian Resuscitation in Sepsis Evaluation (ARISE) Investigators and the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD) Management Committee. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand (2007) Crit Care Resusc 9:8–18Google Scholar
  27. 27.
    Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW (2004) Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 32:755–759CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang WJ, Frei B (2002) Albumin selectively inhibits TNF{alpha}-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res 55:820–829CrossRefPubMedGoogle Scholar
  29. 29.
    Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR (2002) Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med 30:2175–2182CrossRefPubMedGoogle Scholar
  30. 30.
    The SAFE Study Investigators (2007) Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 357:874–884CrossRefGoogle Scholar
  31. 31.
    Wills BA, Dung NM, Loan HT, Tam DTH, Thuy TTN, Minh LTT, Diet TV, Hao NT, Chau NV, Stepniewska K, White NJ, Farrar JJ (2005) Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 353:877–889CrossRefPubMedGoogle Scholar
  32. 32.
    McCann KB, Vucica Y, Famulari S, Bertolini J (2009) Effect of processing methods on colouration of human serum albumin preparations. Biologicals 37:32–36CrossRefPubMedGoogle Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2010

Authors and Affiliations

  1. 1.The SAFE Study Investigators, c/o ANZICS CTG (Prof. S. Finfer)CarltonAustralia

Personalised recommendations